Title (en)

COMPOSITION COMPRISING GLUTATHIONE ENHANCERS AND VITAMINES FOR THE TREATMENT OF AIDS, CANCER AND DIABETES

Title (de)

ZUSAMMENSETZUNG ENTHALTEND EINE GLUTATHION ERHÖHENDE SUBSTANZ UND VITAMINE ZUR BEHANDLUNG VON AIDS, KREBS UND DIABETES

Title (fr)

COMPOSITION COMPRENANT UN STIMULANT DU GLUTATHIONE ET DES VITAMINES POUR LE TRAITEMENT DU SIDA, CANCER ET DIABETE

Publication

EP 0604433 B1 20000315 (EN)

Application

EP 92913917 A 19920604

Priority

• US 9204653 W 19920604
• US 71153091 A 19910606

Abstract (en)

[origin: WO9221368A1] A composition and method for its use in treatement of an immune disorder in a mammal. The composition includes, in relative amounts, between 50 and 3000 mg of a purified compound selected from oxidized and unoxidized gamma-L-glutamyl-L-cysteinylglycine, gamma-L-glutamyl-L-cysteine, N-acetyl-L-cysteine, N-acetyl-L-cysteine-glycine, and any other pharmaceutically active compound which directly enhances the level of gamma-L-glutamyl-L-cysteinylglycine in a mammal, and any salt or ester of said compound, between 50 and 3000 mg purified L-glutamine, between 50 and 10,000 mg purified vitamin C, between 50 and 500 mg purified vitamin E, between 10 and 100 mg purified Beta-carotene, and between 1 and 25 mg purified vitamin B6.

IPC 1-7

A61K 38/00; C07K 5/08; C07K 5/06

IPC 8 full level

A61K 33/24 (2019.01); A61K 38/04 (2006.01); A61K 38/06 (2006.01)

CPC (source: EP US)

A61K 31/07 (2013.01 - EP US); A61K 31/195 (2013.01 - EP US); A61K 31/355 (2013.01 - EP US); A61K 31/375 (2013.01 - EP US); A61K 31/44 (2013.01 - EP US); A61K 31/505 (2013.01 - EP US); A61K 31/51 (2013.01 - EP US); A61K 31/525 (2013.01 - EP US); A61K 31/714 (2013.01 - EP US); A61K 33/04 (2013.01 - EP US); A61K 33/06 (2013.01 - EP US); A61K 33/24 (2013.01 - EP US); A61K 33/26 (2013.01 - EP US); A61K 33/30 (2013.01 - EP US); A61K 38/04 (2013.01 - EP US); A61K 38/063 (2013.01 - EP US)

C-Set (source: EP US)

1. A61K 38/063 + A61K 33/30 + A61K 33/26 + A61K 33/24 + A61K 33/06 + A61K 33/04 + A61K 31/714 + A61K 31/525 + A61K 31/51 + A61K 31/505 + A61K 31/44 + A61K 31/375 + A61K 31/355 + A61K 31/195 + A61K 31/07
2. A61K 31/525 + A61K 2300/00
3. A61K 31/714 + A61K 2300/00
4. A61K 33/04 + A61K 2300/00
5. A61K 33/06 + A61K 2300/00
6. A61K 33/24 + A61K 2300/00
7. A61K 33/26 + A61K 2300/00
8. A61K 33/30 + A61K 2300/00
9. A61K 38/04 + A61K 2300/00
10. A61K 38/063 + A61K 2300/00
11. A61K 38/04 + A61K 33/30 + A61K 33/26 + A61K 33/24 + A61K 33/06 + A61K 33/04 + A61K 31/714 + A61K 31/525 + A61K 31/51 + A61K 31/505 + A61K 31/44 + A61K 31/375 + A61K 31/355 + A61K 31/195 + A61K 31/07
12. A61K 31/07 + A61K 2300/00
13. A61K 31/195 + A61K 2300/00
14. A61K 31/355 + A61K 2300/00
15. A61K 31/375 + A61K 2300/00
16. A61K 31/44 + A61K 2300/00
17. A61K 31/505 + A61K 2300/00
18. A61K 31/51 + A61K 2300/00

Designated contracting state (EPC)

DE FR GB

DOCDB simple family (publication)

WO 9221368 A1 19921210; AU 2187992 A 19930108; DE 69230796 D1 20000420; EP 0604433 A1 19940706; EP 0604433 A4 19941012; EP 0604433 B1 20000315; US 5977073 A 19991102

DOCDB simple family (application)

US 9204653 W 19920604; AU 2187992 A 19920604; DE 69230796 T 19920604; EP 92913917 A 19920604; US 71153091 A 19910606